ArticleInfectious diseases and therapy2024

Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65.

Robert Buynak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.